BACKGROUND & AIMS: Hepatopulmonary syndrome (HPS) affects 10%-30% of patients with cirrhosis and portal hypertension and significantly increases mortality. Studies in experimental models indicate that pulmonary angiogenesis contributes to the development of HPS, but pathogenesis in humans is poorly understood. We investigated genetic risk factors for HPS in patients with advanced liver disease. METHODS: We performed a multicenter case-control study of patients with cirrhosis being evaluated for liver transplantation. Cases had an alveolar-arterial oxygen gradient > or = 15 mm Hg (or > or =20 mm Hg if age > 64 years) and contrast echocardiography with late appearance of microbubbles after venous injection of agitated saline (intrapulmonary vasodilatation); controls did not meet both criteria for case status. The study sample included 59 cases and 126 controls. We genotyped 1086 common single nucleotide polymorphisms (SNPs) in 94 candidate genes. RESULTS: Forty-two SNPs in 21 genes were significantly associated with HPS after adjustments for race and smoking. Eight genes had at least 2 SNPs associated with disease: CAV3, ENG, NOX4, ESR2, VWF, RUNX1, COL18A1, and TIE1. For example, rs237872 in CAV3 showed an odds ratio of 2.75 (95% confidence interval: 1.65-4.60, P = .0001) and rs4837192 in ENG showed an odds ratio of 0.35 (95% confidence interval: 0.14-0.89, P = .027). Furthermore, variation in CAV3 and RUNX1 was associated with HPS in gene-based analyses. CONCLUSIONS: Polymorphisms in genes involved in the regulation of angiogenesis are associated with the risk of HPS. Further investigation of these biologic pathways might elucidate the mechanisms that mediate the development of HPS in certain patients with severe liver disease. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
BACKGROUND & AIMS:Hepatopulmonary syndrome (HPS) affects 10%-30% of patients with cirrhosis and portal hypertension and significantly increases mortality. Studies in experimental models indicate that pulmonary angiogenesis contributes to the development of HPS, but pathogenesis in humans is poorly understood. We investigated genetic risk factors for HPS in patients with advanced liver disease. METHODS: We performed a multicenter case-control study of patients with cirrhosis being evaluated for liver transplantation. Cases had an alveolar-arterial oxygen gradient > or = 15 mm Hg (or > or =20 mm Hg if age > 64 years) and contrast echocardiography with late appearance of microbubbles after venous injection of agitated saline (intrapulmonary vasodilatation); controls did not meet both criteria for case status. The study sample included 59 cases and 126 controls. We genotyped 1086 common single nucleotide polymorphisms (SNPs) in 94 candidate genes. RESULTS: Forty-two SNPs in 21 genes were significantly associated with HPS after adjustments for race and smoking. Eight genes had at least 2 SNPs associated with disease: CAV3, ENG, NOX4, ESR2, VWF, RUNX1, COL18A1, and TIE1. For example, rs237872 in CAV3 showed an odds ratio of 2.75 (95% confidence interval: 1.65-4.60, P = .0001) and rs4837192 in ENG showed an odds ratio of 0.35 (95% confidence interval: 0.14-0.89, P = .027). Furthermore, variation in CAV3 and RUNX1 was associated with HPS in gene-based analyses. CONCLUSIONS: Polymorphisms in genes involved in the regulation of angiogenesis are associated with the risk of HPS. Further investigation of these biologic pathways might elucidate the mechanisms that mediate the development of HPS in certain patients with severe liver disease. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
Authors: T Klemm; A K Mehnert; A Siegemund; T D Wiesner; G Gelbrich; M Blüher; R Paschke Journal: Exp Clin Endocrinol Diabetes Date: 2005-12 Impact factor: 2.949
Authors: Bao Luo; Lichuan Liu; Liping Tang; Junlan Zhang; Cecil R Stockard; William E Grizzle; Michael B Fallon Journal: J Hepatol Date: 2003-05 Impact factor: 25.083
Authors: Dominador J Manalo; Ashley Rowan; Tera Lavoie; Lakshmi Natarajan; Brian D Kelly; Shui Q Ye; Joe G N Garcia; Gregg L Semenza Journal: Blood Date: 2004-09-16 Impact factor: 22.113
Authors: Harprit Singh; Christopher S Milner; Maria M Aguilar Hernandez; Nisha Patel; Nicholas P J Brindle Journal: Cell Signal Date: 2009-04-17 Impact factor: 4.315
Authors: Steven M Kawut; Susan S Ellenberg; Michael J Krowka; David Goldberg; Hugo Vargas; David Koch; Tiffany Sharkoski; Nadine Al-Naamani; Alyson Fox; Robert Brown; Joshua Levitsky; Jae K Oh; Grace Lin; Nianfu Song; Carl Mottram; Margaret F Doyle; David E Kaplan; Samir Gupta; Michael B Fallon Journal: Liver Transpl Date: 2019-05-30 Impact factor: 5.799